K-252a and staurosporine promote choline acetyltransferase activity in rat spinal cord cultures.
The protein kinase inhibitor K-252a increased choline acetyltransferase (ChAT) activity in rat embryonic spinal cord cultures in a dose-dependent manner (EC50 of approximately 100 nM) with maximal stimulatory activity at 300 nM resulting in as much as a fourfold increase. A single application of K-252a completely prevented the marked decline in ChAT activity occurring over a 5-day period following culture initiation. Of 11 kinase inhibitors, only the structurally related inhibitor staurosporine also increased ChAT activity (EC50 of approximately 0.5 nM). Effective concentrations of K-252a were not cytotoxic or mitogenic and did not alter the total protein content of treated cultures. Insulin-like growth factor I, basic fibroblast growth factor, ciliary neurotrophic factor, and leukemia inhibitory factor yielded dose-dependent increases in ChAT activity in spinal cord cultures. The combination of K-252a with insulin-like growth factor-I or basic fibroblast growth factor increased ChAT activity up to eightfold over that of untreated controls, which was greater than that observed with each compound alone. K-252a combined with ciliary neurotrophic factor or leukemia inhibitory factor demonstrated no additive or synergistic effects on ChAT activity. These results suggest that there are multiple mechanisms for the regulation of ChAT activity in spinal cord cultures. The enhancement of spinal cord ChAT activity by K-252a and staurosporine defines a new neurotrophic activity for these small organic molecules and raises the possibility that they may activate some regulatory elements in common with the ciliary neurotrophic factor and leukemia inhibitory factor family of neurotrophic proteins.
Cephalon, Inc., West Chester, Pennsylvania 19380.
M A
MA
Glicksman
J E
JE
Prantner
S L
SL
Meyer
M E
ME
Forbes
M
M
Dasgupta
M E
ME
Lewis
N
N
Neff
D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D002227:Carbazoles / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002795:Choline O-Acetyltransferase / Q000378:metabolism*; D020934:Ciliary Neurotrophic Factor; D026121:Indole Alkaloids; D008934:Mitogens / Q000494:pharmacology; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology; D009414:Nerve Growth Factors / Q000494:pharmacology; D009419:Nerve Tissue Proteins / Q000494:pharmacology; D009474:Neurons / Q000166:cytology / Q000502:physiology; D010275:Parasympathetic Nervous System / Q000166:cytology; D047428:Protein Kinase Inhibitors; D051381:Rats; D013116:Spinal Cord / Q000166:cytology / Q000187:drug effects / Q000201:enzymology*; D019311:Staurosporine; D013997:Time Factors
D000470:Alkaloids; D002227:Carbazoles; D020934:Ciliary Neurotrophic Factor; D026121:Indole Alkaloids; D008934:Mitogens; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D047428:Protein Kinase Inhibitors; C049985:staurosporine aglycone; D002795:Choline O-Acetyltransferase; D019311:Staurosporine